ABSTRACT
Ceftriaxone-induced immune hemolytic anemia (CIHA) is the second most common cause of drug-induced hemolytic anemia. Prompt recognition of this drug reaction is essential because brisk hemolysis can be deadly. The extent to which ceftriaxone antibodies persist after CIHA is unknown; rechallenging patients who have experienced CIHA is not recommended. We report a case of CIHA in a neurooncology patient, which is the first to show anticeftriaxone antibodies with Rh specificity and persisted for 8 months after the drug reaction. These findings have implications for understanding the mechanism of CIHA.
Subject(s)
Anemia, Hemolytic, Autoimmune/chemically induced , Anti-Bacterial Agents/adverse effects , Brain Neoplasms/immunology , Ceftriaxone/adverse effects , Glioma/immunology , Antibodies/blood , Ceftriaxone/immunology , Child, Preschool , Female , HumansSubject(s)
Blood Specimen Collection , Diethylhexyl Phthalate/toxicity , Plasticizers/toxicity , Adolescent , Female , Humans , MaleSubject(s)
Anemia, Sickle Cell/therapy , Blood Group Antigens/immunology , Blood Group Incompatibility/therapy , Erythrocyte Transfusion/methods , Black or African American , Anemia, Sickle Cell/blood , Anemia, Sickle Cell/complications , Anemia, Sickle Cell/epidemiology , Blood Donors , Blood Group Incompatibility/blood , Blood Group Incompatibility/epidemiology , Blood Group Incompatibility/etiology , Child , District of Columbia , Erythrocyte Transfusion/adverse effects , Humans , Isoantibodies/blood , Program EvaluationSubject(s)
Blood Transfusion , Infant, Newborn, Diseases/therapy , Australia , Blood Component Transfusion/adverse effects , Blood Component Transfusion/standards , Blood Component Transfusion/statistics & numerical data , Blood Safety/standards , Blood Transfusion/legislation & jurisprudence , Blood Transfusion/standards , Directed Tissue Donation/legislation & jurisprudence , Europe , Global Health , Graft vs Host Disease/prevention & control , Hematocrit , Humans , Infant, Newborn , Intensive Care, Neonatal , Practice Guidelines as Topic , Risk Management/organization & administration , Transfusion Reaction , United States , Virus Inactivation/radiation effectsABSTRACT
A unique presentation of perinatally acquired hepatitis C (HCV) with acute jaundice and chronic aggressive liver disease in a previously asymptomatic preadolescent is described. The difficulties in establishing the diagnosis and the importance of confirmatory testing for HCV in cryptogenic liver disease are discussed.
